ClinicalTrials.gg
CompletedNCT02814097Updated Sep 7, 2017

A Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection Fraction

A Phase 2 interventional study of elamipretide and Placebo in Chronic Heart Failure, sponsored by Stealth BioTherapeutics Inc.. Completed at 9 sites in 2 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-09-07.

Sponsored by Stealth BioTherapeutics Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 48 studies in Heart Failure with a site in Serbia — 10 open to participants now, 11 under way, 3 of them phase 3. Heart Failure · Serbia.

Enrollment
33rd of 42
46 · median 291
Started
2016
with 5 others
Phase 2
10 of 48
1 open now
Registered
24th of 48
by date
Lead sponsor
2 of 48
Stealth BioTherapeutics Inc.

Among the 48 studies in Heart Failure with a site in Serbia, this one is the 33rd largest by enrollment of the 42 interventional ones that give a count, is one of 6 that started in 2016, is one of 10 in phase 2, and was the 24th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

10 of the 48 studies in Heart Failure with a site in Serbia are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Serbia have not opened yet or have stopped. Only those recruiting at a site in Serbia →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Heart Failure with a site in Serbia, or all of them as a file.
02

Study summary

This is a multi-center, randomized, double-blind, placebo-controlled study in subjects with stable heart failure with preserved ejection fraction (HFpEF) to evaluate the effects of 4 weeks treatment with subcutaneous MTP-131 (elampretide) on left ventricular function.

03

Conditions studied

  • Chronic Heart Failure

Browse trials for

Keywords

  • Heart Failure
  • HFpEF
  • elamipretide
  • MTP-131
  • Bendavia™
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥45 and \<80 years.
  • Symptomatic heart failure (i.e. II or III) due to HFpEF for at least 6 months prior to study start
  • Evidence of HFpEF: ≥45% and E/e´>10 and NT-pro-BNP >220 pg/ml (sinus rhythm) / > 600 pg/mL (atrial fibrillation)
  • An exercise-induced increase in E/e' of at least 1.5 units during stress echocardiography assessment.
  • Heart failure is considered to be stable, in the judgment of the investigator, and no hospitalization for HFpEF or changes in dose regimen of pharmacologic treatment for HF has occurred within 1 month prior to the Screening Visit.
  • Treatment with appropriate pharmacologic therapy to manage underlying risk factors according to current guidelines.
  • Women of must agree to use 1 of the following methods of from the date they sign the ICF until two months after the last dose of study medication:

    a) Abstinence, b) surgically sterilized male partner, or c) barrier method And hormonal contraception

  • Women of child-bearing potential must have a negative serum pregnancy test at baseline
  • Willing and able to provide signed form (ICF) prior to participation in any study-related procedures

Exclusion criteria

Exclusion Criteria:

  • Probable alternative diagnoses that in the opinion of the investigator could account for the patient's symptoms e.g. severe pulmonary dysfunction or severe asthma
  • \<45% (at the moment of enrollment or in medical history)
  • Coronary or peripheral revascularization procedures, valvular procedures, OR any major surgical procedure within 3 months prior to the Screening Visit.
  • Acute coronary syndrome (ACS), stroke or (TIA) within 3 months prior to the Screening Visit.
  • Uncontrolled hypertension defined as a systolic blood pressure (BP) >160 mm Hg or a diastolic BP >100 mm Hg on at least 2 consecutive readings that will require a change in anti-hypertensive treatment during the study period.
  • Active cancer or undergoing chemotherapy within previous 6 months
  • Total >2x the (ULN) in the absence of Gilbert's Syndrome (M. Meulengracht) and liver enzymes ( [ALT] and/or aspartate aminotransferase [AST] and/or alkaline phosphatase) elevation >3xULN
  • Estimated \<30 mL/min, by MDRD
  • Known active drug or alcohol abuse within 1 year of the Screening Visit.
  • Use of other drugs at the time of enrolment, or within 30 days or 5 half-lives of enrolment
  • Treatment with spironolactone or eplerenone for less than 3 months at study start
  • Treatment with dabigatran
  • Treatment with valsartan/sacubitril
  • Female subjects who are pregnant, planning to become pregnant, or lactating.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    40 mg elamipretide

    40 mg elamipretide once daily for 28 consecutive days

    Drug: elamipretide

  • Placebo comparator
    Placebo

    Placebo once daily for 28 consecutive days

    Drug: Placebo

Interventions

  • Subcutaneous injection of 40 mg elamipretide once daily for 28 consecutive days

    Also known as: MTP-131, Bendavia

  • DrugPlacebo

    Subcutaneous injection of placebo administered once daily for 28 consecutive days

06

What researchers measure

Primary outcomes

  1. Compare the delta in E/e' at rest exercise measured with echocardiography between the elamipretide and placebo groups

    Time frame: 4 weeks

Secondary outcomes

  1. Compare the change at rest and during submaximal stress in LV systolic global longitudinal strain (GLS) between the elamipretide and placebo groups at the end of the 4-week treatment period

    Time frame: 4 weeks

  2. Compare the change in 6-minute walking distance, between the elamipretide and placebo groups at the end of the 4-week treatment period

    Time frame: 4 weeks

  3. Compare the change in NT-proBNP, between the elamipretide and placebo groups at the end of the 4-week treatment period

    Time frame: 4 weeks

  4. Compare the percent of patients on elamipretide versus placebo presenting with TEAEs and SAEs, including changes in biomarkers of myocardial damage and changes in markers of renal function

    Time frame: 4 weeks

07

Study locations

9 sites
  • Charite Universitatsmedizin Berlin, Campus Virchow-Klinikum
    Berlin, 13353, Germany
  • German Heart Center
    Berlin, 13353, Germany
  • Clinical Centre of Serbia, Clinic for Cardiology
    Belgrade, 11000, Serbia
  • Clinical Hospital Center "Dr Dragiša Mišović-Dedinje", Department of Cardiology
    Belgrade, 11000, Serbia
  • Clinical Hospital Center "Zvezdara", Department of Cardiology
    Belgrade, 11000, Serbia
  • Clinical Hospital Center "Bežanijska Kosa", Department of Cardiology
    Belgrade, 11080, Serbia
  • Clinical Hospital Center "Zemun", Department of Cardiology
    Belgrade, 11080, Serbia
  • Clinical Center Niš, Clinic for Cardiology
    Niš, 18000, Serbia
  • Institute for Cardiovascular Diseases Vojvodina, Clinic for Cardiology
    Sremska Kamenica, 21204, Serbia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2016 to primary completion in May 2017, 8 months.

Of 74 industry-sponsored phase 2 interventional studies under Heart Failure, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 31. This study's 8 months is below that.

Counting every sponsor, half of 185 studies reached it within 29 months; a quarter within 17 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2016
First posted
Jun 27, 2016
StartActual
Sep 2, 2016
Primary completionActual
May 4, 2017
CompletionActual
Jun 2, 2017
Last update
Sep 7, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 7, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02814097
Collaborators
Charite University, Berlin, Germany, SCIRENT Clinical Research and Science d.o.o.
Responsible party
Sponsor
First posted
Jun 27, 2016
Start date
Sep 2, 2016
Primary completion
May 4, 2017
Completion
Jun 2, 2017
Last update
Sep 7, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elamipretide

Start the discussion